Increased levels of obesity
and diabetes have caused a sharp rise in the prevalence of Peripheral Vascular
Disease (PVD) in recent years and will contribute to the expansion of the Drug
Eluting Balloons (DEB) market, business intelligence specialist GlobalData has
The new report* suggests that the value of the market is expected to almost
double by 2017, reaching a value of $127 million. This will largely be due to
an increase in physician uptake as long-term clinical data is released
supporting their effectiveness and as the device is adopted for new indications
such as PVD. US Food and Drug Administration (FDA) product approvals over the
next two to three years are also expected to boost future uptake, playing on
the existing importance of the US market and the current unmet need in the
interventional cardiology devices market.
Of course, with further budget cuts expected for the healthcare industry in
2012, cost and patient compliance are two additional factors promoting the use
of DEBs. Offering improved efficacy and patient safety for some indications,
these products have the potential to create a niche market. In fact,
preliminary clinical trial results suggest that DEBs could become the standard
treatment for PVD and complex lesions in the future.
GlobalData analysts suggest that PVD, Small Vessel Disease (SVD), bifurcated lesions
and In-Stent Restenosis (ISR) could represent a $2 billion untapped market.
This market is set to be further boosted by the complications associated with
long-term antiplatelet therapy. The risks of bleeding and contraindications
limit current interventions and further the potential of DEBs in the healthcare
Among the products set to contribute to the growth of the DEB market is B.
Braun's product, SeQuent Please, which currently accounts for the highest
number of completed and ongoing clinical trials. Bayer's PACCOCATH technology
has also demonstrated success in animal models and both these products are
expected to receive regulatory approval in the next two to three years.
(Source - GLOBALDATA,